{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:49:16Z","timestamp":1784735356423,"version":"3.55.0"},"reference-count":82,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T00:00:00Z","timestamp":1778371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Prostate cancer (PCa) screening has long relied on PSA testing, a strategy that has shaped diagnostic pathways for decades but remains limited by substantial overdiagnosis and downstream overtreatment. As screening practices evolve, the relevance of historical evidence must be reconsidered in the context of contemporary diagnostic workflows that now incorporate imaging, refined biopsy techniques, and risk-adapted management. This narrative review examines the transition from PSA-only screening toward modern, risk-adapted early detection strategies. We synthesize evidence supporting the integration of mpMRI, refined biopsy techniques, and active surveillance (AS) as key components of contemporary screening pathways aimed at improving the detection of clinically significant disease while minimizing unnecessary interventions. Particular emphasis is placed on second-line MRI-based approaches, which consistently reduce the number of avoidable biopsies and enhance the diagnostic precision. In addition, we review the role of blood-based and genomic biomarkers in pre-biopsy risk stratification, discussing established tools within a unified framework of individualized screening. The review also contextualizes very recent regulatory developments, including the FDA approval of a novel structure-based PSA assay, as part of the ongoing evolution of biomarker-supported screening rather than a paradigm shift. Overall, this article provides a timely synthesis of mature randomized evidence and emerging diagnostic innovations, offering a clinically grounded perspective on how PCa screening is being reshaped toward more personalized and harm-aware strategies.<\/jats:p>","DOI":"10.3390\/cancers18101547","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:05:22Z","timestamp":1778501122000},"page":"1547","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prostate Cancer Screening in Contemporary Era: PSA-Based Testing and Risk-Adapted Approaches"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0348-7698","authenticated-orcid":false,"given":"Michele","family":"Brancaccio","sequence":"first","affiliation":[{"name":"Division of Urology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5880-0584","authenticated-orcid":false,"given":"Armando","family":"Galdieri","sequence":"additional","affiliation":[{"name":"Division of Urology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5987-4659","authenticated-orcid":false,"given":"Andrea","family":"Cosenza","sequence":"additional","affiliation":[{"name":"Division of Urology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Barletta","sequence":"additional","affiliation":[{"name":"Division of Urology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Scilipoti","sequence":"additional","affiliation":[{"name":"Division of Urology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Quarta","sequence":"additional","affiliation":[{"name":"Division of Urology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Zaurito","sequence":"additional","affiliation":[{"name":"Division of Urology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0284-346X","authenticated-orcid":false,"given":"Alfonso","family":"Santangelo","sequence":"additional","affiliation":[{"name":"Division of Urology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0567-404X","authenticated-orcid":false,"given":"Alessandro","family":"Viti","sequence":"additional","affiliation":[{"name":"Division of Urology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1102-6381","authenticated-orcid":false,"given":"Angelo","family":"Occhi","sequence":"additional","affiliation":[{"name":"Division of Urology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elena","family":"Porzi","sequence":"additional","affiliation":[{"name":"Division of Urology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Colistro","sequence":"additional","affiliation":[{"name":"Division of Urology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Roca","sequence":"additional","affiliation":[{"name":"Division of Urology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Scuderi","sequence":"additional","affiliation":[{"name":"Division of Urology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Cucchiara","sequence":"additional","affiliation":[{"name":"Division of Urology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Stabile","sequence":"additional","affiliation":[{"name":"Division of Urology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[{"name":"Division of Urology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"},{"name":"Vita-Salute San Raffaele University, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[{"name":"Division of Urology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"},{"name":"Vita-Salute San Raffaele University, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Gandaglia","sequence":"additional","affiliation":[{"name":"Division of Urology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"},{"name":"Vita-Salute San Raffaele University, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,10]]},"reference":[{"key":"ref_1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/imj.12407","article-title":"Prostate cancer: Measuring PSA","volume":"44","author":"Pezaro","year":"2014","journal-title":"Intern. Med. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10334-022-01006-6","article-title":"The role of MRI in prostate cancer: Current and future directions","volume":"35","author":"Fernandes","year":"2022","journal-title":"Magn. Reson. Mater. Phys. Biol. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"W226","DOI":"10.2214\/AJR.18.19880","article-title":"Head-to-Head Comparison Between Biparametric and Multiparametric MRI for the Diagnosis of Prostate Cancer: A Systematic Review and Meta-Analysis","volume":"211","author":"Woo","year":"2018","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): A paired validating confirmatory study","volume":"389","author":"Ahmed","year":"2017","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.eururo.2018.11.040","article-title":"The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies","volume":"75","author":"Wegelin","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1470-2045(25)00100-7","article-title":"Local anaesthetic transperineal biopsy versus transrectal prostate biopsy in prostate cancer detection (TRANSLATE): A multicentre, randomised, controlled trial","volume":"26","author":"Bryant","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"345","DOI":"10.21037\/tau.2017.01.13","article-title":"Cost consideration in utilization of multiparametric magnetic resonance imaging in prostate cancer","volume":"6","author":"Hutchinson","year":"2017","journal-title":"Transl. Androl. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41391-024-00840-0","article-title":"Evaluation of blood and urine based biomarkers for detection of clinically-significant prostate cancer","volume":"28","author":"Robinson","year":"2025","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1200\/JCO.2009.24.2180","article-title":"Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer","volume":"28","author":"Klotz","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.2014.55.1192","article-title":"Long-term follow-up of a large active surveillance cohort of patients with prostate cancer","volume":"33","author":"Klotz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Methley, A.M., Campbell, S., Chew-Graham, C., McNally, R., and Cheraghi-Sohi, S. (2014). PICO, PICOS and SPIDER: A comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews. BMC Health Serv. Res., 14.","DOI":"10.1186\/s12913-014-0579-0"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1001\/jama.1993.03510080052031","article-title":"Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening","volume":"270","author":"Catalona","year":"1993","journal-title":"JAMA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1001\/jama.1996.03530350019021","article-title":"Free serum prostate-specific antigen and screening for prostate cancer","volume":"275","author":"Bangma","year":"1996","journal-title":"JAMA"},{"key":"ref_16","first-page":"23","article-title":"Randomized trials of PSA screening","volume":"43","author":"Dave","year":"2025","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","article-title":"Screening and prostate-cancer mortality in a randomized European study","volume":"360","author":"Hugosson","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1113135","article-title":"Prostate-cancer mortality at 11 years of follow-up","volume":"366","author":"Hugosson","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","article-title":"Screening and prostate cancer mortality: Results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up","volume":"384","author":"Hugosson","year":"2014","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","article-title":"A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer","volume":"76","author":"Hugosson","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1056\/NEJMoa2503223","article-title":"European Study of Prostate Cancer Screening\u201423-Year Follow-up","volume":"393","author":"Roobol","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S1470-2045(10)70146-7","article-title":"Mortality results from the G\u00f6teborg randomised population-based prostate-cancer screening trial","volume":"11","author":"Hugosson","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/JU.0000000000002696","article-title":"Results from 22 years of Followup in the G\u00f6teborg Randomized Population-Based Prostate Cancer Screening Trial","volume":"208","author":"Godtman","year":"2022","journal-title":"J. Urol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"449","DOI":"10.7326\/M16-2586","article-title":"Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials","volume":"167","author":"Tsodikov","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e1919284","DOI":"10.1001\/jamanetworkopen.2019.19284","article-title":"Association of Baseline Prostate-Specific Antigen Level with Long-term Diagnosis of Clinically Significant Prostate Cancer Among Patients Aged 55 to 60 Years: A Secondary Analysis of a Cohort in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial","volume":"3","author":"Kovac","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1001\/jama.2018.0154","article-title":"Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial","volume":"319","author":"Martin","year":"2018","journal-title":"JAMA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2024.4011","article-title":"Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial","volume":"331","author":"Martin","year":"2024","journal-title":"JAMA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.3399\/bjgp20X713957","article-title":"Prostate-specific antigen testing and opportunistic prostate cancer screening: A cohort study in England, 1998\u20132017","volume":"71","author":"Clift","year":"2021","journal-title":"Br. J. Gen. Pract."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.juro.2016.08.092","article-title":"Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Arm","volume":"197","author":"Halpern","year":"2017","journal-title":"J. Urol."},{"key":"ref_30","first-page":"309","article-title":"Ten-Year Trends in Digital Rectal Exam Results and Prostate Cancer Detection: Insights from the PLCO Trial","volume":"17","author":"Guan","year":"2025","journal-title":"Res. Rep. Urol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1002\/ijc.33940","article-title":"A randomized trial of risk-adapted screening for prostate cancer in young men-Results of the first screening round of the PROBASE trial","volume":"150","author":"Arsov","year":"2022","journal-title":"Int. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.euo.2023.09.008","article-title":"Digital Rectal Examination Is Not a Useful Screening Test for Prostate Cancer","volume":"6","author":"Krilaviciute","year":"2023","journal-title":"Eur. Urol. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1080\/21681805.2021.1966095","article-title":"Digital rectal examination in prostate cancer screening at PSA level 3.0\u20133.9\u2009ng\/mL: Long-term results from a randomized trial","volume":"55","author":"Soronen","year":"2021","journal-title":"Scand. J. Urol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamaoncol.2020.7456","article-title":"Population-Based Prostate Cancer Screening with Magnetic Resonance Imaging or Ultrasonography: The IP1-PROSTAGRAM Study","volume":"7","author":"Burak","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e059482","DOI":"10.1136\/bmjopen-2021-059482","article-title":"Prostate MRI versus PSA screening for prostate cancer detection (the MVP Study): A randomised clinical trial","volume":"12","author":"Nam","year":"2022","journal-title":"BMJ Open"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.euf.2024.02.006","article-title":"Opportunistic Prostate Cancer Screening with Biparametric Magnetic Resonance Imaging (VISIONING)","volume":"10","author":"Wetterauer","year":"2024","journal-title":"Eur. Urol. Focus"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.eururo.2025.11.024","article-title":"Primary Noncontrast Magnetic Resonance Imaging for Prostate Cancer Screening: A Randomized Clinical Trial (PROSA)","volume":"89","author":"Messina","year":"2025","journal-title":"Eur. Urol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa2100852","article-title":"MRI-Targeted or Standard Biopsy in Prostate Cancer Screening","volume":"385","author":"Eklund","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.eururo.2024.01.017","article-title":"Prostate Cancers in the Prostate-specific Antigen Interval of 1.8\u20133 ng\/mL: Results from the G\u00f6teborg-2 Prostate Cancer Screening Trial","volume":"86","author":"Hugosson","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1056\/NEJMoa2209454","article-title":"Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only","volume":"387","author":"Hugosson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMoa2406050","article-title":"Results after Four Years of Screening for Prostate Cancer with PSA and MRI","volume":"391","author":"Hugosson","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.annonc.2020.06.025","article-title":"Imaging-based prostate cancer screening among BRCA mutation carriers\u2014Results from the first round of screening","volume":"31","author":"Segal","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/S1470-2045(15)00361-7","article-title":"Prostate cancer screening in men aged 50\u201369 years (STHLM3): A prospective population-based diagnostic study","volume":"16","author":"Adolfsson","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1200\/JCO.24.00152","article-title":"Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered Trial","volume":"42","author":"Vigneswaran","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2025.10.001","article-title":"Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial","volume":"89","author":"Vigneswaran","year":"2026","journal-title":"Eur. Urol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Karlsson, A.A., Hao, S., Jauhiainen, A., Elfstr\u00f6m, K.M., Egevad, L., Nordstr\u00f6m, T., Heintz, E., and Clements, M.S. (2021). The cost-effectiveness of prostate cancer screening using the Stockholm3 test. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0246674"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.eururo.2014.10.021","article-title":"A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer","volume":"68","author":"Parekh","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.eururo.2024.04.037","article-title":"Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the G\u00d6TEBORG-2 Prostate Cancer Screening Trial","volume":"86","author":"Josefsson","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jama.2024.3841","article-title":"Prostate Cancer Screening with PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial","volume":"331","author":"Auvinen","year":"2024","journal-title":"JAMA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1158\/1055-9965.EPI-24-1877","article-title":"Evaluation of the 4Kscore Test in Relation to Subsequent Risk of Aggressive Prostate Cancer in the European Prospective Investigation into Cancer and Nutrition","volume":"34","author":"Fensom","year":"2025","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_52","first-page":"1","article-title":"Use of the 4Kscore test to predict the risk of aggressive prostate cancer prior to prostate biopsy: Overall cost savings and improved quality of care to the us healthcare system","volume":"19","author":"Voigt","year":"2017","journal-title":"Rev. Urol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/pcan.2016.72","article-title":"Use of the Prostate Health Index for detection of prostate cancer: Results from a large academic practice","volume":"20","author":"Tosoian","year":"2017","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.juro.2010.12.032","article-title":"A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng\/mL prostate specific antigen range","volume":"185","author":"Catalona","year":"2011","journal-title":"J. Urol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.eururo.2011.03.052","article-title":"Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng\/mL: Results of a prospective study in a clinical setting","volume":"60","author":"Guazzoni","year":"2011","journal-title":"Eur. Urol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41391-017-0008-7","article-title":"Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting","volume":"21","author":"White","year":"2018","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jval.2015.12.002","article-title":"The Cost-Effectiveness of Prostate Cancer Detection with the Use of Prostate Health Index","volume":"19","author":"Heijnsdijk","year":"2016","journal-title":"Value Health"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa2407934","article-title":"Assessment of a Polygenic Risk Score in Screening for Prostate Cancer","volume":"392","author":"McHugh","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.eururo.2026.01.031","article-title":"Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT Study","volume":"89","author":"Bancroft","year":"2026","journal-title":"Eur. Urol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/pros.24182","article-title":"Prospective study of diagnostic accuracy in the detection of high-grade prostate cancer in biopsy-na\u00efve patients with clinical suspicion of prostate cancer who underwent the Select MDx test","volume":"81","author":"Dominguez","year":"2021","journal-title":"Prostate"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Roumigui\u00e9, M., Ploussard, G., Nogueira, L., Brugui\u00e8re, E., Meyrignac, O., Lesourd, M., P\u00e9ricart, S., and Malavaud, B. (2020). Independent Evaluation of the Respective Predictive Values for High-Grade Prostate Cancer of Clinical Information and RNA Biomarkers after Upfront MRI and Image-Guided Biopsies. Cancers, 12.","DOI":"10.3390\/cancers12020285"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/bju.13861","article-title":"van Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics\u2014A decision analytical model","volume":"120","author":"Dijkstra","year":"2017","journal-title":"BJU Int."},{"key":"ref_63","first-page":"e205","article-title":"PCA3 Urinary Biomarker for Prostate Cancer","volume":"12","author":"Loeb","year":"2010","journal-title":"Rev. Urol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1080\/14737140.2018.1502086","article-title":"The role of prostate cancer antigen 3 (PCA3) in prostate cancer detection","volume":"18","author":"Ploussard","year":"2018","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/jamaoncol.2017.0177","article-title":"Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer","volume":"3","author":"Sanda","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1001\/jamaoncol.2024.0455","article-title":"Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer","volume":"10","author":"Tosoian","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1001\/jamaoncol.2016.0097","article-title":"A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy","volume":"2","author":"McKiernan","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.eururo.2023.12.015","article-title":"Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial","volume":"86","author":"Hu","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.euo.2024.01.019","article-title":"Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Biopsies for Prostate Cancer Diagnosis: Final Results of the Randomized PERFECT trial (CCAFU-PR1)","volume":"7","author":"Ploussard","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.eururo.2022.01.008","article-title":"Targeted Prostate Biopsy: Umbra, Penumbra, and Value of Perilesional Sampling","volume":"82","author":"Brisbane","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Baboudjian, M., Uleri, A., Anract, J., Brabant, L., Assenmacher, G., Baudewyns, A., Peyrottes, A., Sanguedolce, F., Fiard, G., and Renard-Penna, R. (Eur. Urol. Oncol., 2026). Targeted, Perilesional, and Distant Biopsies in Prostate Cancer, Eur. Urol. Oncol., in press.","DOI":"10.1016\/j.euo.2026.02.006"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.eururo.2024.03.014","article-title":"PRECISE Version 2: Updated Recommendations for Reporting Prostate Magnetic Resonance Imaging in Patients on Active Surveillance for Prostate Cancer","volume":"86","author":"Englman","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.eururo.2012.11.005","article-title":"Active surveillance for low-risk prostate cancer worldwide: The PRIAS study","volume":"63","author":"Bul","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.eururo.2018.06.025","article-title":"Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial","volume":"75","author":"Klotz","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.eururo.2019.10.007","article-title":"Randomized Study of Systematic Biopsy Versus Magnetic Resonance Imaging and Targeted and Systematic Biopsy in Men on Active Surveillance (ASIST): 2-year Postbiopsy Follow-up","volume":"77","author":"Klotz","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/JU.0000000000000742","article-title":"Risk of Metastasis in Men with Grade Group 2 Prostate Cancer Managed with Active Surveillance at a Tertiary Cancer Center","volume":"203","author":"Carlsson","year":"2020","journal-title":"J. Urol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1097\/JU.0000000000000713","article-title":"Long-Term Outcomes of Active Surveillance for Prostate Cancer: The Memorial Sloan Kettering Cancer Center Experience","volume":"203","author":"Carlsson","year":"2020","journal-title":"J. Urol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.juro.2016.06.102","article-title":"Active Surveillance for Intermediate Risk Prostate Cancer: Survival Outcomes in the Sunnybrook Experience","volume":"196","author":"Musunuru","year":"2016","journal-title":"J. Urol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.eururo.2025.06.012","article-title":"Active Surveillance for Screen-detected Low- and Intermediate-risk Prostate Cancer: Extended Follow-up up to 25 Years in the G\u00d6TEBORG-1 Trial","volume":"88","author":"Palmstedt","year":"2025","journal-title":"Eur. Urol."},{"key":"ref_80","unstructured":"SRCTN Registry [Internet] (2026, March 08). Trial of Randomised Approaches for National Screening for Men (TRANSFORM). Available online: https:\/\/www.isrctn.com\/ISRCTN13801649."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1080\/14737167.2025.2543464","article-title":"Cost-effectiveness of MRI strategies for early prostate cancer detection: A systematic review","volume":"25","author":"Khalili","year":"2025","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/MOU.0000000000001293","article-title":"Cost-effectiveness of serum, urine, and tissue-based prostate cancer biomarkers","volume":"35","author":"Gupta","year":"2025","journal-title":"Curr. Opin. Urol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/10\/1547\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:24:45Z","timestamp":1778502285000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/10\/1547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,10]]},"references-count":82,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["cancers18101547"],"URL":"https:\/\/doi.org\/10.3390\/cancers18101547","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,10]]}}}